## Anna L Goodman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7489016/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2022, 10, 167-179.	10.7	89
2	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. Lancet, The, 2022, 399, 36-49.	13.7	161
3	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. Annals of Internal Medicine, 2022, 175, 234-243.	3.9	56
4	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	5.0	26
5	COVID-19 vaccine results might inform malaria vaccine strategies. Lancet Infectious Diseases, The, 2022, 22, 440-441.	9.1	1
6	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial Journal of Infection, 2022, 84, 795-813.	3.3	43
7	A multisite evaluation of antifungal use in critical care: implications for antifungal stewardship. JAC-Antimicrobial Resistance, 2022, 4, .	2.1	1
8	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet Infectious Diseases, The, 2022, 22, 1131-1141.	9.1	99
9	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	13.7	3,887
10	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 905-914.	27.0	357
11	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): updated guidelines from the UK. JAC-Antimicrobial Resistance, 2021, 3, dlaa114.	2.1	77
12	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA): updated guidelines from the UK. Journal of Antimicrobial Chemotherapy, 2021, 76, 1377-1378.	3.0	26
13	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	13.7	979
14	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	13.7	540
15	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med, 2021, 2, 701-719.e19.	4.4	73
16	Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infectious Diseases, The, 2021, 21, 939-949.	9.1	744
17	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	4.7	190
18	Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. New England Journal of Medicine, 2021, 385, 1172-1183.	27.0	734

Anna L Goodman

#	Article	IF	CITATIONS
19	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T <sub>H</sub> 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	12.4	80
20	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	30.7	900
21	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	13.7	214
22	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infectious Diseases, The, 2021, 21, 1345-1347.	9.1	26
23	Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity. Clinical Infection in Practice, 2021, 12, 100089.	0.5	11
24	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 2258-2276.	13.7	519
25	Effect of awake prone positioning in hypoxaemic adult patients with COVID-19. Journal of the Intensive Care Society, 2020, , 175114372096124.	2.2	6
26	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open, 2020, 10, e038847.	1.9	4
27	Experience of a novel community testing programme for COVID-19 in London: Lessons learnt. Clinical Medicine, 2020, 20, e165-e169.	1.9	13
28	Evaluation of Microbiological Sampling Practice in Community Acquired Pneumonia at a South London Trust: The Cheaper, the Better?. Access Microbiology, 2020, 2, .	0.5	0
29	Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 668-678.	13.7	140
30	Bawa-Garba case: an objective view on diagnosing group A streptococcal sepsis. Clinical Medicine, 2018, 18, 438-438.	1.9	0
31	Nonantibiotic prevention and management of recurrent urinary tract infection. Nature Reviews Urology, 2018, 15, 750-776.	3.8	155
32	Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against <i><scp>M</scp>ycobacterium bovis</i> bacillus Calmette–GuA©rin challenge in mice. Immunology, 2015, 146, 264-270.	4.4	8
33	Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax. Frontiers in Immunology, 2015, 6, 348.	4.8	44
34	Pericardial mass and cardiac tamponade associated with Mycoplasma pneumoniae. Clinical Medicine, 2015, 15, 106-107.	1.9	0
35	Intractable diarrhoea despite immune reconstitution in an HIV positive man. Journal of Clinical Virology, 2015, 69, 219-222.	3.1	1
36	Awareness of Meningococcal Disease among Travelers from the United Kingdom to the Meningitis Belt in Africa. American Journal of Tropical Medicine and Hygiene, 2014, 91, 281-286.	1.4	13

Anna L Goodman

#	Article	IF	CITATIONS
37	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nature Communications, 2013, 4, 2836.	12.8	256
38	The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706.	3.3	36
39	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. Journal of Infectious Diseases, 2012, 205, 772-781.	4.0	194
40	T Cell Responses Induced by Adenoviral Vectored Vaccines Can Be Adjuvanted by Fusion of Antigen to the Oligomerization Domain of C4b-Binding Protein. PLoS ONE, 2012, 7, e44943.	2.5	23
41	The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nature Communications, 2011, 2, 601.	12.8	233
42	A Viral Vectored Prime-Boost Immunization Regime Targeting the Malaria Pfs25 Antigen Induces Transmission-Blocking Activity. PLoS ONE, 2011, 6, e29428.	2.5	56
43	Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. Journal of Antimicrobial Chemotherapy, 2011, 66, 1815-1820.	3.0	80
44	Prime-boost vectored malaria vaccines: Progress and prospects. Hum Vaccin, 2010, 6, 78-83.	2.4	184
45	New Candidate Vaccines against Blood-Stage <i>Plasmodium falciparum</i> Malaria: Prime-Boost Immunization Regimens Incorporating Human and Simian Adenoviral Vectors and Poxviral Vectors Expressing an Optimized Antigen Based on Merozoite Surface Protein 1. Infection and Immunity, 2010, 78. 4601-4612.	2.2	46
46	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105.	11.0	65
47	Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine, 2009, 27, 5589-5598.	3.8	19
48	Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821.	30.7	148
49	Tuberculosis. Clinical Medicine, 2008, 8, 531-534.	1.9	6
50	Central airway obstruction caused by a peripheral hamartoma. Lung Cancer, 2007, 57, 395-398.	2.0	6
51	Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: A randomised trial. Lung Cancer, 2006, 54, 51-55.	2.0	57
52	Trouble comes in twos. BMJ: British Medical Journal, 2005, 330, 1079.	2.3	0
53	CIGUATERA POISONING IN VANUATU. American Journal of Tropical Medicine and Hygiene, 2003, 68, 263-266.	1.4	10
54	Ciguatera poisoning in Vanuatu. American Journal of Tropical Medicine and Hygiene, 2003, 68, 263-6.	1.4	1